Rocket Pharmaceuticals Inc [RCKT] stock is trading at $7.23, down -2.69%. An important factor to consider is whether the stock is rising or falling in short-term value. The RCKT shares have gain 14.22% over the last week, with a monthly amount drifted -5.98%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rocket Pharmaceuticals Inc [NASDAQ: RCKT] stock has seen the most recent analyst activity on March 12, 2025, when BMO Capital Markets initiated its Outperform rating and assigned the stock a price target of $50. Previously, Wedbush started tracking the stock with Outperform rating on December 30, 2024, and set its price target to $32. On December 18, 2024, Jefferies initiated with a Buy rating and assigned a price target of $29 on the stock. Scotiabank started tracking the stock assigning a Sector Outperform rating. Goldman initiated its recommendation with a Neutral and recommended $39 as its price target on April 02, 2024. Cantor Fitzgerald started tracking with a Overweight rating for this stock on October 24, 2023, and assigned it a price target of $65. In a note dated February 01, 2023, Morgan Stanley initiated an Overweight rating and provided a target price of $45 on this stock.
Rocket Pharmaceuticals Inc [RCKT] stock has fluctuated between $4.55 and $26.98 over the past year. Currently, Wall Street analysts expect the stock to reach $35.5 within the next 12 months. Rocket Pharmaceuticals Inc [NASDAQ: RCKT] shares were valued at $7.23 at the most recent close of the market. An investor can expect a potential return of 391.01% based on the average RCKT price forecast.
Analyzing the RCKT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is -0.64 and Total Capital is -0.56. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.11 points at the first support level, and at 6.98 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.38, and for the 2nd resistance point, it is at 7.52.
Ratios To Look Out For
For context, Rocket Pharmaceuticals Inc’s Current Ratio is 9.30. On the other hand, the Quick Ratio is 9.30, and the Cash Ratio is 4.02.
Transactions by insiders
Recent insider trading involved Militello John,, that happened on Apr 22 ’25 when 718.0 shares were sold. Officer, Militello John completed a deal on Apr 22 ’25 to buy 718.0 shares. Meanwhile, CEO Shah Gaurav bought 20000.0 shares on Apr 10 ’25.
